ZNTL Jun 2024 10.000 call
| Previous Close | 3.1000 |
| Open | 3.1000 |
| Bid | 0.0000 |
| Ask | 4.9000 |
| Strike | 10.00 |
| Expire Date | 2024-06-21 |
| Day's Range | 3.1000 - 3.1000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 9 |
Simply Wall St.We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
GlobeNewswireZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK & SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on June 3, 2024, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 20,000 shares of the Company’s common stock to two newly
GuruFocus.comInsider Selling at Zentalis Pharmaceuticals Inc (ZNTL): President, Interim CFO Cam Gallagher ...
On May 31, 2024, Cam Gallagher, President and Interim Chief Financial Officer of Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL), sold 9,597 shares of the company.
